Federal Circuit Finds No Error in District Court Determination the Claimed Invention was not Obvious
In Endo Pharmaceutical Solutions, Inc. v. Custopharm Inc., [2017-1719] (July 13, 2018), the Federal Circuit affirmed the determination that the claims of U.S. Patent Nos. 7,718,640 and 8,338,395 on a long-acting injectable testosterone replacement therapy were not invalid for obviousness. the district … Continue reading Federal Circuit Finds No Error in District Court Determination the Claimed Invention was not Obvious
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed